Sultanate of Oman. The Directorate General of Pharmaceutical Affairs and Drug Control (DGPA&DC) of Oman has approved the addition of the following information in the package insert of meloxicam (Moven) capsules:

Drug Interaction: Meloxicam is not recommended with concomitant aspirin therapy due to the possibility of an increase in gastrointestinal ulceration or other complications.

Side Effects: Concomitant use of meloxicam, 15 mg once daily, and lithium doses ranging from 804 to 1072 mg twice daily are known to result in an increase in the mean pre-dose lithium concentration and the area under the curve by 21% when compared to subjects receiving lithium alone. This results from an inhibition of renal prostaglandin synthesis by meloxicam.

Reference:

Pharmaceutical Newsletter of the Ministry of Health, Sultanate of Oman, vol. 10 (1), 2002.